{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:28:27Z","timestamp":1761989307407,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"name":"GSK"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pearl Therapeutics"},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Theravance"},{"name":"Forest"},{"name":"Circassia"},{"name":"GSK"},{"name":"Innoviva"},{"name":"Mylan"},{"name":"Verona"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.anai.2019.02.016","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T01:29:33Z","timestamp":1551058173000},"page":"478-485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma"],"prefix":"10.1016","volume":"122","author":[{"given":"Geoffrey","family":"Chupp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel N.","family":"Kline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary T.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Zangrilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Trudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.anai.2019.02.016_bib1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"year":"2017","series-title":"Fasenra\u2122 (benralizumab) [prescribing information]","key":"10.1016\/j.anai.2019.02.016_bib2"},{"issue":"10056","key":"10.1016\/j.anai.2019.02.016_bib6","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.anai.2019.02.016_bib7","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.anai.2019.02.016_bib8","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2019.02.016_bib9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/all.13374","article-title":"Identification of patterns of factors preceding severe or life-threatening asthma exacerbations in a nationwide study","volume":"73","author":"Tanaka","year":"2018","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2019.02.016_bib10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1164\/ajrccm.160.2.9811100","article-title":"FACET international study group. Exacerbation of asthma: a descriptive study of 425 severe exacerbations","volume":"160","author":"Tattersfield","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"10.1016\/j.anai.2019.02.016_bib13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa042552","article-title":"Daily versus as-needed corticosteroids for mild persistent asthma","volume":"352","author":"Boushey","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2019.02.016_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes in asthma measures in a clinical trial?","volume":"14","author":"Santello","year":"1999","journal-title":"Eur Respir J"},{"year":"2014","series-title":"Bayesian Data Analysis","author":"Gelman","key":"10.1016\/j.anai.2019.02.016_bib15"},{"key":"10.1016\/j.anai.2019.02.016_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10928-014-9373-1","article-title":"Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response","volume":"41","author":"Marostica","year":"2014","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.anai.2019.02.016_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.rmed.2005.08.012","article-title":"Identifying \u2018well-controlled\u2019 and \u2018not well-controlled\u2019 asthma using the Asthma Control Questionnaire","volume":"100","author":"Juniper","year":"2006","journal-title":"Respir Med"},{"year":"2017","series-title":"Fasenra\u2122 (benzalizumab) \u2013 SIROCCO and CALIMA FEV1 Data at Week 4 [scientific data on file]","key":"10.1016\/j.anai.2019.02.016_bib18"},{"issue":"11","key":"10.1016\/j.anai.2019.02.016_bib19","doi-asserted-by":"crossref","first-page":"e0166833","DOI":"10.1371\/journal.pone.0166833","article-title":"Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.anai.2019.02.016_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A\u00a0randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"issue":"3","key":"10.1016\/j.anai.2019.02.016_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000444799","article-title":"A\u00a0phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan","volume":"169","author":"Park","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"10.1016\/j.anai.2019.02.016_bib22","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12325-018-0727-8","article-title":"Rapid and consistent improvements in morning PEF in patients with severe eosinophilic asthma treated with mepolizumab","volume":"35","author":"Ortega","year":"2018","journal-title":"Adv Ther"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619301292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619301292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:22:13Z","timestamp":1761052933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619301292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1081120619301292"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.02.016","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}